What the buyer wrote
Embedding blood group genotyping into routine practice. The primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- Blood Group Genotyping for Sickle Cell and Thalassaemia
- How they are buying
- Given to one supplier, no competitionNobody else was asked, and the buyer has to be able to justify that.
- Work starts
- 19 Dec 2025
- Work ends
- 31 Mar 2026
- Where
- in London
Who the buyer named
The buyer published a contact address on this notice.